Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1326

Similar articles for PubMed (Select 16755113)

1.

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.

Sawaki M, Ito Y, Akiyama F, Tokudome N, Horii R, Mizunuma N, Takahashi S, Horikoshi N, Imai T, Nakao A, Kasumi F, Sakamoto G, Hatake K.

Breast Cancer. 2006;13(2):172-8.

2.

Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.

Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF.

Hum Pathol. 2002 Jan;33(1):105-10.

PMID:
11823980
3.

Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.

Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB.

J Clin Oncol. 2000 May;18(10):2070-80.

PMID:
10811672
4.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

5.

C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.

Sharifah NA, Lee BR, Clarence-Ko CH, Tan GC, Shiran MS, Naqiyah I, Rohaizak M, Fuad I, Tamil AM.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):663-70.

6.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
7.

Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.

Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, Bilgi S.

Exp Oncol. 2005 Jun;27(2):145-9. Erratum in: Exp Oncol. 2005 Dec;27(4):346. Fusun, Tokatli [corrected to Tokatli, Fusun]; Semsi, Altaner [corrected to Altaner, Semsi]; Cem, Uzal [corrected to Cem, Uzal]; Mevlut, Ture [corrected to Ture, Mevlut]; Zafer, Kocak [corrected to Kocak, Zafer] Kazim, Uygun [corrected to Uygun, Kazim]; Selcuk, Bilgi [corrected to Bilgi, Selcuk].

PMID:
15995634
8.

HER-2/neu oncogene expression in advanced breast cancer.

Krogerus LA, Leivonen M.

Cancer Detect Prev. 2001;25(1):1-7.

PMID:
11270416
10.

Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.

Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Cancer. 2003 Apr 1;97(7):1591-600.

11.

Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.

Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD.

Ann Surg. 1994 Apr;219(4):332-41.

12.
13.

Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.

Poltinnikov IM, Rudoler SB, Tymofyeyev Y, Kennedy J, Anne PR, Curran WJ Jr.

Am J Clin Oncol. 2006 Feb;29(1):71-9.

PMID:
16462507
14.

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M.

Int J Oncol. 1999 Apr;14(4):663-71.

PMID:
10087312
15.

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P.

J Pathol. 2004 Mar;202(3):265-73.

PMID:
14991891
16.

p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U.

J Natl Cancer Inst. 1993 Jun 16;85(12):965-70.

PMID:
8496982
17.

Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.

Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS.

Cancer. 2004 Feb 1;100(3):499-506.

18.

Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.

Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.

Anticancer Res. 2004 May-Jun;24(3b):2061-8.

19.

Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.

el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A.

Anticancer Res. 2002 Jul-Aug;22(4):2493-9.

PMID:
12174951
20.

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.

Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC.

J Clin Oncol. 2003 Feb 1;21(3):453-7.

PMID:
12560434
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk